A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.

Abstract

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.

• Authors: Chengyuan Liang, Lei Tian, Yuzhi Liu, Nan Hui, Guaiping Qiao, Han Li, Zhenfeng Shi, Yonghong Tang, Dezhu Zhang, Xiaolin Xie, Xu Zhao
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 201 Pg. 112527 (Sep 01 2020) ISSN: 1768-3254 [Electronic] France
• PMID: 32563812 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Chemical References

• Antiviral Agents
• remdesivir
• Adenosine Monophosphate
• Alanine

Topics

• Adenosine Monophosphate (analogs & derivatives, therapeutic use)
• Alanine (analogs & derivatives, therapeutic use)
• Antiviral Agents (therapeutic use)
• Betacoronavirus (drug effects)
• COVID-19
• Clinical Trials as Topic
• Coronavirus Infections (drug therapy, virology)
• Humans
• Pandemics
• Pneumonia, Viral (drug therapy, virology)
• SARS-CoV-2
• COVID-19 Drug Treatment